These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 7914949

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. p53 expression and K-ras mutation in colorectal adenomas.
    Scott N, Bell SM, Sagar P, Blair GE, Dixon MF, Quirke P.
    Gut; 1993 May; 34(5):621-4. PubMed ID: 8504962
    [Abstract] [Full Text] [Related]

  • 4. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
    Hsieh JS, Lin SR, Chang MY, Chen FM, Lu CY, Huang TJ, Huang YS, Huang CJ, Wang JY.
    Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
    [Abstract] [Full Text] [Related]

  • 5. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.
    Bouzourene H, Gervaz P, Cerottini JP, Benhattar J, Chaubert P, Saraga E, Pampallona S, Bosman FT, Givel JC.
    Eur J Cancer; 2000 May; 36(8):1008-15. PubMed ID: 10885605
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Overexpression of p53 protein and proliferative activity in colorectal adenoma.
    Yamaguchi A, Makimoto K, Goi T, Takeuchi K, Maehara M, Isobe Y, Nakagawara G.
    Oncology; 1994 May; 51(3):224-7. PubMed ID: 7910956
    [Abstract] [Full Text] [Related]

  • 8. Prognostic significance of p53 and ras p21 expression in nonsmall cell lung cancer.
    Fujino M, Dosaka-Akita H, Harada M, Hiroumi H, Kinoshita I, Akie K, Kawakami Y.
    Cancer; 1995 Dec 15; 76(12):2457-63. PubMed ID: 8625071
    [Abstract] [Full Text] [Related]

  • 9. Microvessel density, cyclo-oxygenase 2 expression, K-ras mutation and p53 overexpression in colonic cancer.
    Liang JT, Huang KC, Jeng YM, Lee PH, Lai HS, Hsu HC.
    Br J Surg; 2004 Mar 15; 91(3):355-61. PubMed ID: 14991639
    [Abstract] [Full Text] [Related]

  • 10. [Cell kinetics of colorectal tumors with assessment by K-ras mutation and PCNA labeling index].
    Tanaka M, Omura K, Ishida F, Watanabe Y.
    Nihon Geka Gakkai Zasshi; 1993 Dec 15; 94(12):1249-55. PubMed ID: 7903793
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer.
    Tortola S, Marcuello E, González I, Reyes G, Arribas R, Aiza G, Sancho FJ, Peinado MA, Capella G.
    J Clin Oncol; 1999 May 15; 17(5):1375-81. PubMed ID: 10334521
    [Abstract] [Full Text] [Related]

  • 16. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.
    Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M, Hurwitz HI, Kabbinavar F, Novotny WF, Hillan KJ, Koeppen H.
    J Natl Cancer Inst; 2005 Jul 06; 97(13):981-9. PubMed ID: 15998951
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.
    Bland KI, Konstadoulakis MM, Vezeridis MP, Wanebo HJ.
    Ann Surg; 1995 Jun 06; 221(6):706-18; discussion 718-20. PubMed ID: 7794075
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.